Aurobindo Pharma gets USFDA nod for its expectorant tablets
Drug firm Aurobindo Pharma on Thursday said it has received final nod from the US health regulator for its Guaifenesin extended-release tablets used as expectorant. The company has received final approval from the United States Food and Drug Administration (USFDA) to manufacture its generic Guaifenesin extended-release tablets in the strengths of 600 mg and 1,200 mg, Aurobindo Pharma said in a filing to the BSE.
The product is expected to be launched in the fourth quarter of 2019-20, it added.
The company's tablets are the generic version of RB Health (US) LLC's Mucinex tablets, Aurobindo Pharma said.